Back to search results

Levetiracetam vs. Magnesium Sulfate for Preventing Eclamptic Seizures

This study is comparing two medications, levetiracetam and magnesium sulfate, to see if they are equally effective at preventing eclamptic seizures in pregnant or postpartum women. Eclamptic seizures can be a serious complication of severe preeclampsia, a condition where you have high blood pressure during pregnancy. The study aims to enroll 1240 women aged 19 or older who have severe preeclampsia or related conditions and are at risk for seizures. Researchers want to see if levetiracetam can prevent seizures just as well as magnesium sulfate, while also looking at side effects and outcomes for both mothers and babies. The study's current status is unclear.

Study design
This is a randomized controlled trial, meaning participants will be randomly assigned to receive either levetiracetam or magnesium sulfate. The study aims to enroll 1240 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for eclamptic seizures from enrollment until the end of monitoring at 6 weeks postpartum.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07220902

Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure

Not Yet Recruiting
PHASE3Ages 19+InterventionalPrevention
Nebraska Methodist Health System
~1,240 participants
Updated 2025-10-24 on ClinicalTrials.gov
What's tested:Levetiracetammagnesium sulfate

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Eclamptic Seizure
Measured over From enrollment until then end of monitoring at 6 weeks postpartum.

Conditions

Severe Preeclampsia
Eclampsia Preeclampsia

Explore related trials

HELLP SyndromePreeclampsia

Where it's being run

1 sites across 1 states
Nebraska1

Study leadership

  • Todd Lovgren, MD · PRINCIPAL_INVESTIGATOR · Nebraska Methodist Health System

Who to contact

Todd Lovgren, MD
[email protected]
1+402-815-1970
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pregnant or postpartum women aged 19 years or older
Diagnosed with preeclampsia with severe features, superimposed preeclampsia or HELLP syndrome
At risk for eclampsia and eligible for seizure prophylaxis
Less than 2 hours exposure to magnesium sulfate or greater than 48 hours since last dose.
Admitted or plan to proceed with delivery

Exclusion

\<32 weeks estimated gestational age
History of epilepsy or seizure disorders unrelated to pregnancy
Allergy or contraindication to Levetiracetam or Magnesium Sulfate
Severe renal impairment (Oliguria \<120ml in 4 hours)
Plan for neonatal comfort care

What this trial measures

  • Eclamptic SeizureFrom enrollment until then end of monitoring at 6 weeks postpartum.

    Seizure based on clinical diagnosis by managing physician. It will be considered and eclamptic seizure for purposes of the study if it occurs following enrollment in the study.